Interferon-alpha intranasal - Adhera Therapeutics
Alternative Names: Intranasal interferon - alphaLatest Information Update: 12 Nov 2021
Price :
$50 *
At a glance
- Originator Nastech Pharmaceutical Company
- Developer Marina Biotech
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Immunostimulants; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Hepatitis B; Hepatitis C
Most Recent Events
- 03 Feb 2017 Discontinued - Phase-I for Cancer in USA (Intranasal)
- 03 Feb 2017 Discontinued - Phase-I for Hepatitis B in USA (Intranasal)
- 03 Feb 2017 Discontinued - Phase-I for Hepatitis C in USA (Intranasal)